HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Allogeneic or autologous bone marrow transplantation for acute non-lymphocytic leukemia in first remission.

Abstract
One hundred and seven consecutive patients with acute non-lymphocytic leukemia (ANL) aged less than 56 years were allocated to receive either allogeneic (allo-BMT) or autologous bone marrow transplantation (auto-BMT) when first complete remission (CR1) was achieved. CR was obtained in 96 patients. Twenty-four patients had an HLA-identical sibling donor and 20 of these (83%) had an allograft in CR1. Thirty-three patients (44% of the CR1 patients without donor) had an autograft in CR1. The reasons for not transplanting patients in CR1 were early relapse (nine patients), refusal (11 patients) or medical problems (23 patients). The 4-year leukemia-free survival (LFS) probability for all the CR1 patients was 25%. For the allo-BMT patients, the 4-year LFS was 71%, and for the auto-BMT patients 31% (log-rank p = 0.028). The relapse probabilities were 33% and 48% respectively (p = 0.40). If the results are analysed according to the intent of the protocol, patients with a donor had an LFS of 53%, and patients without a donor an LFS of 16% (p = 0.003). This study confirms the value of allo-BMT for consolidation of ANL in CR1. The attempt to autograft all CR1 patients without a compatible donor has not resulted in any marked improvement of LFS.
AuthorsA Ferrant, C Doyen, A Delannoy, G Cornu, P Martiat, D Latinne, M De Bruyère, A Bosly, J L Michaux, G Sokal
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 7 Issue 4 Pg. 303-9 (Apr 1991) ISSN: 0268-3369 [Print] England
PMID2070137 (Publication Type: Comparative Study, Journal Article)
Topics
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Belgium (epidemiology)
  • Bone Marrow Transplantation
  • Combined Modality Therapy
  • Evaluation Studies as Topic
  • Female
  • Humans
  • Leukemia, Myeloid, Acute (drug therapy, mortality, surgery)
  • Life Tables
  • Male
  • Middle Aged
  • Outcome and Process Assessment, Health Care
  • Prognosis
  • Remission Induction
  • Survival Rate
  • Transplantation, Autologous
  • Transplantation, Homologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: